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Abstract
Background: CD26 (dipeptidyl peptidase IV, DPPIV) is a 110 kDa surface glycoprotein expressed in most normal
tissues, and is a potential novel therapeutic target for selected cancers. Our work evaluates the mechanism
involved in confluence-dependent CD26 expression in colon cancer.
Methods: Colon adenocarcinoma cells were grown to confluence, and expression of CD26 and transcription
factors implicated in its regulation was confirmed by immunofluorescence and Western blotting. Real-time PCR
was also performed to evaluate CD26 upregulation at the transcriptional level. The influence of c-Myc on CD26
expression during different growth conditions was further evaluated following transient transfection of a c-Myc-
expressing plasmid and a c-Myc specific siRNA.
Results: We found that the colon cancer cell lines HCT-116 and HCT-15 exhibited a confluence-dependent
increase in CD26 mRNA and protein, associated with decreased expression of c-Myc, increased USF-1 and Cdx 2
levels, and unchanged HNF-1a expression. Meanwhile, ectopic expression of c-Myc in both cell lines led to
decreased CD26 expression. In contrast, transfection of a siRNA targeted to Cdx2 resulted in decreased CD26 level.
Importantly, culturing of cells in serum-depleted media, but not acidic conditions, upregulated CD26. While HIF-1a
level also increased when cells were cultured in serum-depleted media, its expression was required but not
sufficient for CD26 upregulation.
Conclusions: CD26 mRNA and protein levels increase in a confluence-dependent manner in colon carcinoma cell
lines, with c-Myc acting as a repressor and Cdx2 acting as an enhancer of CD26 expression. The enhanced
expression of CD26 in serum-depleted media and a requirement for HIF-1a suggest a role for nutrients or growth
factors in the regulation of CD26 protein expression.
Background
CD26/dipeptidyl peptidase IV is a 110 kDa surface gly-
coprotein with diverse functional properties which
include peptidase activity and functional and physical
association with key molecules in various signal trans-
duction pathways [1,2]. During the past decades, CD26
has been shown to participate in T-cell biology as a
costimulatory molecule able to regulate signaling trans-
duction pathways [3-5]. In addition to its role in T-cell
biology, recent studies have shown that CD26 also plays
an important role in tumor biology.
Furthermore, CD26 itself may be a novel therapeutic
target. Anti-CD26 monoclonal antibody (mAb) treatment
results in both in vitro and in vivo antitumor activity
against several tumor types, including lymphoma,
mesothelioma and renal cell carcinoma [6-8].
However, CD26 expression varies among different cell
lines and tumor histologies, resulting in conflicting
reports regarding the role of CD26 in the development
of different neoplasms, including colon cancer [1]. For
example, CD26 is upregulated during enterocytic differ-
entiation of the colon adenocarcinoma cell lines Caco-2
and HT-29 [9]. Interestingly, trypsinizing and seeding
late post-confluent Caco-2 cells led to reduced CD26
expression and dipeptidyl peptidase IV activity, as well
as the disappearance of other differentiation markers
such as sucrase isomaltase and GLUT5 [10]. However,
the precise mechanism responsible for this cell density-
dependent regulation of CD26 expression and dipeptidyl
peptidase IV activity has not been fully elucidated.
* Correspondence: nam.dang@medicine.ufl.edu
2Division of Hematology/Oncology, University of Florida, Gainesville, FL
32610, USA
Full list of author information is available at the end of the article
Abe et al. BMC Cancer 2011, 11:51
http://www.biomedcentral.com/1471-2407/11/51
© 2011 Abe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Compared with most normal tissues, solid tumors tend
to exhibit high cell density due to rapid growth, and
high cell density has been linked to anti-cancer drug
resistance [11,12]. In view of the emerging role of CD26
as a novel therapeutic target, we investigated the
mechanism of confluence-dependent expression of
CD26 to further understand CD26 biology.
In this paper, we investigated the mechanism involved
in the confluence-dependent increase in CD26 expres-
sion in the colon cancer cell lines HCT-116 and
HCT-15. We demonstrated that c-Myc is involved in
the regulation of CD26 expression as a repressor of
transcription in both cell lines, and that Cdx2 signifi-
cantly contributes to the confluence-dependent increase
in CD26 expression in HCT-15 cells. Furthermore, we
found that serum-depleted culture conditions, but not
acidic conditions, significantly upregulated CD26 levels,
hence implicating a potential role for nutrients or serum
growth factors in the regulation of CD26 protein
expression.
Methods
Cell culture
The human colorectal carcinoma cell lines HCT-116
and HCT-15 were purchased from the American Type
Culture Collection (ATCC, Manassas, VA). HCT 15,
HCT-116, and HCT-116
HIF1a-/- cells [13] were main-
tained in McCoy’s 5A medium (ATCC) supplemented
with 10% fetal bovine serum (FBS) (Hyclone, South
Logan, Utah), 100 units/ml of penicillin and 100 μg/ml
of streptomycin (Invitrogen) at 37°C and 5% CO2.F o r
confluence-dependent experiments, HCT-116 cells or
HCT-15 cells were seeded at 7.5 × 10
5 cells/6-cm dish
and 1.0 × 10
6 cells/6-cm dish (day-0), respectively, and
were grown several days to obtain a post-confluent
state. Medium was changed daily. For immunofluores-
cence staining, cells were grown on a glass slide in
RPMI-1640 (Hyclone) without phenol red and supple-
mented with 10% FBS, 100 units/ml of penicillin, and
100 μg/ml of streptomycin at 37°C. Cells were cultured
at sub-confluence or post-confluence by changing med-
ium daily. For normoxic culture conditions, cells were
incubated at 37°C, in 5% CO2 and room air (21% O2).
For hypoxic conditions, cells were incubated at 37°C in
a hypoxia chamber (Billups-Rothenberg, Del Mar, CA)
flushed and equilibrated with 1% O2,9 4 %N 2 and 5%
CO2 (Airgas West, Las Vegas, NV). For acidic culture
conditions, cells were cultured in McCoy’s5 Am e d i u m
supplemented with 25 mM 2-N-morpholine ethanesul-
fonic acid (MES, Sigma, St Louis, MO) and 10% FBS
(pH 6.2) under normoxic or hypoxic conditions. For
hypoxic or acidic culture conditions, cells were used at
3 days post-confluence, and grown on the bottom of a
standing flask (25 cm
2)f i l l e dw i t h5 0m lo fc u l t u r e
medium to avoid any change in pH or serum concentra-
tion. For serum depletion experiments, cells were cul-
tured in McCoy’s 5A medium containing 0.3% bovine
serum albumin (BSA, Sigma).
Western blots
Cells were lysed with RIPA buffer [1% NP40, 0.5% deox-
ycholate, 0.1% SDS, 150 mM sodium chloride, 50 mM
Tris-HCl (pH 8.0)] supplemented with Halt protease
inhibitor cocktail (Pierce, Rockford, IL), 5 mM EDTA,
5 mM sodium orthovanadate, 10 mM sodium fluoride
and 1 mM b-glycerophosphate (Sigma). For preparation
of lysates from cells cultured under hypoxic conditions,
100 μMC o C l 2 w a sa d d e dt ot h el y s i sb u f f e rt op r e v e n t
degradation of HIF-1a. Protein concentration was mea-
sured by Micro BCA Protein Assay Kit (Pierce). Lysates
were mixed with Laemmli sample buffer (4X), boiled for
5 minutes at 100°C, and equal amounts of protein
(50 μg per lane for a 10 comb gel) were separated by
SDS-PAGE, followed by overnight wet-transfer to nitro-
cellulose at 4°C. For detection of CD26, samples were
incubated at a lower temperature (37°C for 15 min).
CD26 was detected at 220 kDa as a form of homodimer
which increased detection sensitivity [14]. We confirmed
that the band detected at 220 kDa was depleted in a
dose-dependent manner with anti-CD26 mouse mono-
clonal antibody 1F7 by immunoprecipitation (data not
shown). After blocking with 5% nonfat milk in 0.1%
Tween 20-TBS for 1 hour at room temperature, mem-
branes were incubated with the appropriate primary
antibodies in 1% blocking buffer for 2 hours at room
temperature or overnight at 4°C [anti-CD26 (MI1004,
Calbiochem, San Diego, CA or AF1180, R&D Systems,
Minneapolis, MN), anti-Cdx2 (MU392A-UC, BioGenex,
San Ramon, CA), anti-a-tubulin (T9026, Sigma, Saint
Louis, MO), anti-c-Myc (9E10), anti-USF-1 (C-20), anti-
HNF-1a (C-19) (sc-40, sc-229, and sc-6547, respectively,
Santa Cruz, Santa Cruz, CA)], anti-HIF-1a (610958, BD
Transduction Laboratories, San Jose, CA)], followed by
incubation with the appropriate HRP-conjugated second-
ary antibodies (Pierce) for 1 hour at room temperature.
Membranes were incubated with SuperSignal West Dura
(Pierce) for 5 minutes, and visualized using a KODAK
Image Station 2000R or 4000R (Carestream Health, New
Haven, CT). Some membranes were processed using the
Odyssey Infrared Imaging System by using the appropri-
ate infrared-labeled secondary antibodies in Odyssey
Blocking Buffer (LI-COR Biosciences, Lincoln, NE).
Real-time quantitative PCR for CD26 mRNA expression
Total RNA was isolated from cells with RNeasy Mini Kit
and QIAshredder (Qiagen, Valencia, CA). Equal amounts of
total RNA (90 ng) were analyzed by one step real-time PCR
using QuantiFast SYBR Green RT-PCR and Hs_DPP4_1_SG
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7500 Fast Real Time PCR System (Applied Biosystems, Fos-
ter City, CA). The reaction conditions were as follows: 10
minutes at 50°C (RT step), 5 minutes at 95°C, and 40 cycles
o f1 0s e c o n d sa t9 5 ° Cf o l l o w e db y3 0s e c o n d sa t6 0 ° C .R e l a -
tive changes in CD26 mRNA expression were calculated
based on the 2
-ΔCT method [15].
Immunofluorescence microscopy
Following washing with PBS, cells were fixed with cold
ethanol for 2 min. Cells were air-dried, rehydrated with
PBS, and blocked with 5% BSA in PBS for 30 minutes at
room temperature. After washing with PBS for 3 minutes
(3 times), cells were incubated with anti-CD26 mouse mAb
(202.36, Santa Cruz) for 1 hour at room temperature. Cells
were then washed with PBS and incubated with fluorescein
isothiocyanate (FITC)-conjugated anti-mouse IgG (F8264,
Sigma) for 30 minutes in the dark at room temperature.
After washing with PBS, cells were mounted using Fluoro-
guard™ Antifade (Insitus Biotechnologies, Albuquerque,
NM) and immunofluorescence was visualized using a fluor-
escence microscope (Olympus-BX51, Melville, NY).
Transient transfection for ectopic expression of c-Myc
Confluent HCT-116 and HCT-15 cells (95-100% conflu-
ence) in 6-well plates were transfected with 5 μg/well of
pcDNA3-c-Myc (provided by Dr. Wafik El-Deiry, Uni-
versity of Pennsylvania, through Addgene as a distribu-
tor, Cambridge, MA) or empty vector using 10 μl/well
of Lipofectamine 2000. Cells were grown for several
days, and medium was changed daily.
Transient transfection of Cdx-2 siRNA
HCT-15 cells were grown to 80-90% confluence in 6-well
plates and were transfected with 200 pmol/well of Cdx-2
siRNA (sc-43680, Santa Cruz) or control siRNA
(sc-37007, Santa Cruz) using 7 μl per well of Lipofecta-
mine 2000 (Invitrogen). Medium was changed daily.
Results
Confluence-dependent upregulation of CD26 expression
in HCT-116 and HCT-15 cells
Following incubation of the colon cancer cell lines
HCT-116 and HCT-15 to a post-confluent state, we
detected a confluence-dependent increase in CD26
expression (Figure 1A and 1B), which was regulated at
the mRNA level as shown by real-time PCR (Figure 1C).
The membrane localization of CD26 in both cell lines at
post-confluence was confirmed by immunofluorescence
staining (Figure 1D). This confluence-dependent upre-
gulation of CD26 expression was also observed in three
other solid tumor cell lines: malignant mesothelioma
cell line JMN, colon adenocarcinoma cell line LS174T
and gastric cancer cell line MKN45 (data not shown).
Confluence-dependent expression of transcription factors
c-Myc, USF-1, HNF-1a, and Cdx2 in HCT-116 and HCT-15
cells
To investigate the molecular mechanism involved in the
confluence-dependent expression of CD26, we examined
the expression of transcription factors known to be
involved in regulating CD26 expression. In previous stu-
dies, the ubiquitously expressed cellular upstream stimu-
latory factor 1 (USF-1) and the hepatocyte nuclear factor
1a (HNF-1a) have been reported to exhibit promoter
activity for CD26 expression through binding to their
consensus motifs in the CD26 promoter region in Caco-
2 cells [16,17]. USF-1 is a member of the eukaryotic
evolutionarily conserved basic helix-loop-helix leucine
zipper transcription factor family [18]. HNF-1a was
originally characterized as a liver-specific transcription
factor but is also found in other tissues such as kidney,
small intestine and thymus [19]. Our data from Western
blot analysis show that USF-1 protein expression is
increased in a confluence-dependent manner, while
HNF-1a expression is unchanged for both cell lines,
suggesting that only USF-1 is correlated with the conflu-
ence-dependent increase for CD26 expression (Figure 2).
We also examined the expression of the proto-onco-
gene c-Myc in this process. A transcription factor
belonging to the basic helix-loop-helix leucine zipper
transcription factor family, c-Myc is closely linked to
upregulated proliferation and deregulated cell cycle in
tumors [20]. c-Myc is known to bind to specific DNA
sequences referred to as E-box sequences. USF-1 can
also bind to these sequences, and in fact, c-Myc and
USF-1 have been reported to exert opposing effects on
promoter activity for some genes by competing with
each other to occupy E-box sites [21]. In addition,
c-Myc has been reported to suppress gene expression of
proteins involved in differentiation and cell cycle arrest
such as p15
Ink4b,p 2 1
Cip1 and p27
Kip1 [22]. We now
demonstrate that, unlike our findings with USF-1,
c-Myc expression decreases in a confluence-dependent
manner in both cell lines (Figure 2), suggesting the
involvement of c-Myc as a negative regulator of CD26
expression.
Cdx2 is a member of the caudal-related homeobox gene
family and has emerged as one of the major regulatory fac-
tors controlling intestinal cell differentiation [23]. Previous
work has indicated that the forced expression of Cdx2 in
HIEC cells (a normal human intestinal epithelial crypt cell
model) led to CD26 upregulation [24]. However, Cdx2 can
be phosphorylated by cyclin-dependent kinase 2 (Cdk2),
resulting in ubiquitin-dependent degradation [25]. There-
fore, the increased CD26 expression in HIEC cells was
found to be limited by Cdx2 degradation by proteosomes.
In our studies, there was a dramatic increase in Cdx2 pro-
tein expression in a confluence-dependent manner in
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Figure 1 Confluence-dependent upregulation of CD26 expression in HCT-116 and HCT-15. A) Confluence-dependent changes in CD26
protein expression were analyzed by Western blots. Cells (1 × 10
6) were plated in a 6-cm dish (day 0) and grown to post-confluence, with cells
being confluent on day 3. Each lane was loaded with 50 μg protein. B) Densitometric analysis of the results from Western blots is shown. C)
CD26 mRNA level was measured by real-time quantitative PCR as described in Materials and Methods. D) Immunofluorescence staining of CD26
in HCT-116 and HCT-15 cells on day 7 was performed as described in Materials and Methods. While fluorescence staining was not detectable at
sub-confluence (data not shown), membrane localization of CD26 in both cell lines was demonstrated at post-confluence. All data shown are
representative of three independent experiments.
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Page 4 of 10HCT-15 cells. However Cdx2 was undetectable in HCT-
116 cells at all states of confluence (Figure 2).
Involvement of c-Myc as a repressor of CD26 expression
in HCT-116 and HCT-15 cells
To further investigate c-Myc involvement in regulating
CD26 expression, we transiently transfected c-Myc into
both cell lines at post-confluence. Figure 3 shows that
the over-expression of c-Myc resulted in a significant
decrease in CD26 protein expression. Although c-Myc
over-expression does not completely abrogate the con-
fluence-dependent increase in CD26 expression, these
r e s u l t ss u p p o r tar o l ef o rc - M y ca sar e p r e s s o ro fC D 2 6
expression.
Involvement of Cdx2 in the confluence-dependent
increase in CD26 expression in HCT-15 cells
S i n c ew ed e t e c t e dad r a m a t i ci n c r e a s ei nC d x 2p r o t e i n
expression along with enhanced CD26 level in a conflu-
ence-dependent manner, we next examined whether
Cdx2 is involved in the regulation of CD26 expression.
A ss h o w ni nF i g u r e4 ,t r a n s i e n tt r a n s f e c t i o no fp o s t -
confluent HCT-15 cells using Cdx2 siRNA resulted in
decreased CD26 expression compared to that seen using
the control siRNA. These results indicate a potential
role for Cdx2 in regulating the confluence-dependent
increase in CD26 expression in this cell line.
To evaluate the effect of ectopic expression of Cdx2
on CD26 level, we transiently transfected Cdx2 into
HCT-116 and HCT-15 cells at various states of conflu-
ence. However, we found no significant effect on CD26
expression in either cell line (data not shown). One
potential explanation for these findings is that Cdx2
may exert its effect on the CD26 promoter by combin-
ing with an unknown factor X. Therefore, decreasing
Cdx2 level by siRNA would reduce the putative Cdx2-
factor X complex, leading to a lowered CD26 promoter
activity. This scenario may explain the lack of effect on
CD26 transcription following transient transfection of
Cdx2 alone (without increasing factor X).
Effect of hypoxic, acidic and serum-depleted culture
conditions on CD26 expression in HCT-116 cells
To determine cell culture conditions that might have an
effect on the regulation of CD26 expression, we first
evaluated the effect of hypoxia. The upregulation of
CD26 expression under hypoxic conditions has been
reported previously by ourselves and others [26-28], as
well as the existence of pericellular hypoxia in dense
cultures [12]. Sub-confluent HCT 116 cells were incu-
bated either under normoxic or hypoxic conditions (see
Materials and Methods) for 1, 4, or 24 hours. After a 24
hour incubation, cells were still sub-confluent (~90%),
and there was no difference in pH between normoxic
and hypoxic media. Cells were harvested at the specified
time, lysed, run on gels, and analyzed by Western blots
(Figure 5A). CD26 expression did not change under
hypoxic conditions even when expression of HIF-1a was
HCT-116 HCT-15
N/D
CD26
c-Myc
USF-1
HNF-1D D
D-Tubulin
D a y : 1234 567 1234567
Cdx2
Figure 2 Confluence-dependent upregulation of transcription factors in HCT-116 and HCT-15 cells. Culture conditions were the same as
for Figure 1. Protein expression was analyzed by Western blotting as described in Materials and Methods. Data shown are representative of
three independent experiments. All transcription factors exhibited altered protein expression levels in a confluence-dependent manner except
for HNF-1a, which was unchanged. *N/D, Cdx2 was not detected in HCT-116.
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Page 5 of 10at its highest (following 4 hr hypoxia). In addition, there
was no difference between normoxic and hypoxic cells
with respect to CD26 at 3 days post-confluence (Figure
5B). Although hypoxia alone did not lead to the
enhancement of CD26 (Figure 5A and 5B), HIF-1a level
was increased as cells became more confluent (Figure
5C). It was not detected on day 1 (sub-confluent), but
rose steadily until it peaked at day 4 (1 day post-conflu-
ent), then declined gradually through day 8 (5 days
post-confluent). Comparison of CD26 expression in
confluent and sub-confluent HCT-116 and HCT-116
HIF1a-/- cells revealed significantly higher CD26 expres-
sion for cells that are HIF-1a positive (Figure 5D).
These results suggest that HIF-1a is required, but not
sufficient, for CD26 upregulation.
We next examined whether low extracellular pH
affected CD26 protein expression. HCT-116 cells at
post-confluence or sub-confluence were cultured in
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Figure 3 Effect of c-Myc on confluence-dependent CD26 expression in HCT-116 and HCT-15 cells. The effect of ectopic expression of c-
Myc on the confluence-dependent increase in CD26 protein expression was examined in HCT-116 and HCT-15 cells by transient transfection
using either pcDNA3/c-Myc or the empty vector (control) as described in Materials and Methods. Protein expression was analyzed by Western
blotting (A, B) and quantified by densitometric analysis (C). Data shown are representative of three independent experiments.
Abe et al. BMC Cancer 2011, 11:51
http://www.biomedcentral.com/1471-2407/11/51
Page 6 of 10regular 10% FBS medium at pH 7.3 or acidic 10% FBS
medium supplemented with 25 mM MES at pH 6.2. As
shown in Figure 5E and 5F, the pH of the medium did
n o ta f f e c tC D 2 6e x p r e s s i o ni ns u b - c o n f l u e n to rp o s t -
confluent cultures.
Since nutrients and serum growth factors may be
depleted when cells reach a high cell density, we also
tested the effect of culturing cells in serum-depleted
media. Since the supply of available nutrients and
growth factors may vary in post-confluent cultures, the
use of serum-depleted media may offer a more consis-
tent culture environment to evaluate the role of nutri-
ents and serum growth factors in CD26 expression.
When HCT-116 cells at sub-confluence were cultured
in 0.3% BSA medium without serum for 24 hours,
CD26 protein level was significantly increased compared
to cells cultured in 10% FBS medium (Figure 5F and
5G). HIF-1a level was likewise increased when cells
were cultured in the absence of serum (Figure 5G). On
the other hand, c-Myc expression was decreased in
serum-depleted media. Interestingly, CD26 expression in
cells cultured for 24 hours with 10% FBS (following
24-hour serum depletion) returned to basal level as did
HIF1-a and c-Myc (Figure 5G), demonstrating the
reversibility of this phenomena.
Discussion
In the present study, we demonstrate that CD26 expres-
sion is increased in colon carcinoma lines grown to con-
fluence, associated with changes in selected transcription
factors. In particular, we found that c-Myc expression
decreases with confluence, and that it can act as a
repressor of CD26 expression. In contrast, Cdx2 expres-
sion parallels that of CD26, increasing with confluence.
A potential explanation for the observed confluence-
dependent increase in Cdx2 protein expression may be
due to confluence-mediated cell cycle arrest, resulting in
decreased expression of Cdk2 and decreased phosphory-
lation of Cdx2 by Cdk2, leading to increased Cdx2 pro-
tein expression [25]. Our findings also suggest the
existence of a co-factor X that has a role in regulating
CD26 expression in combination with Cdx2, although
234 5 6
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Figure 4 Effect of Cdx2 siRNA on confluence-dependent CD26 expression in HCT-15 cells. The effect of Cdx2 siRNA on the confluence-
dependent CD26 protein expression in HCT-15 was evaluated following transient transfection (when cells were at 90% confluence) of control
siRNA (left) or Cdx2 siRNA (right) as described in Materials and Methods. CD26 and Cdx2 protein expression were analyzed by Western blotting
and quantified by densitometric analysis. Data shown are representative of three independent experiments.
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Figure 5 Effect of hypoxic, acidic and serum-depleted culture conditions on CD26 expression in HCT-116 cells. A) Effect of hypoxia (1%
O2) on CD26 protein expression in cells at sub-confluence. Cells at ~50% confluence were incubated under hypoxic or normoxic conditions.
Cells were harvested at different time points and protein expression was analyzed by Western blotting as described in Materials and Methods.
B) Effect of hypoxia on CD26 protein expression at 3 days post-confluence. Cells were grown to 3 days post-confluence, then incubated under
hypoxic or normoxic conditions for 24 hours. C) Expression of HIF-1a at sub- and postconfluence. Cells were grown for 8 days, from sub-
confluence through 5 days post-confluence and protein expression was analyzed by Western blotting. D) Enhanced CD26 expression in parental
HCT-116 cells compared to HCT-116
HIF1-a-/- cells. Whole cell lysates (24 μg) were run on gels and analyzed as described previously. Cells were
held at confluence for 3 days (lane 1), 1 day (lane 2), or were sub-confluent (lane 3). E) The effect of acidic conditions on CD26 expression. Cells
were grown to 3 days post-confluence as described above, and then incubated in regular 10% FBS medium (pH 7.3) or in acidic medium
supplemented with 25 mM MES (pH 6.2) for 24 hours. F) The effect of hypoxia, acidic medium, and serum depletion was examined in cells at
sub-confluence. G) The effect of switching cells from serum-depleted culture conditions to 10% FBS medium was evaluated. Cells were grown to
~25% confluence (lane #1) and then cultured in regular 10% FBS medium (lane #2) or serum-depleted medium (lane #3) for 24 hours. Cells
cultured in serum-free medium for 24 hours were re-cultured in regular 10% FBS medium for another 24 hours (lane# 4). Cell confluence at this
point was still ~90%. All data discussed above are representative of at least three independent experiments.
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hypothesis. In addition, we demonstrated that a
hypoxia-induced increase in HIF-1a was not associated
with an enhanced CD26 level, but that HIF-1a expres-
sing cells displayed a higher level of HIF-1a along with
a higher level of CD26 when grown to confluence. In
comparison, a lack of enhancement of HIF-1a and
CD26 levels in HCT-116
HIF1a-/- cells, suggest that HIF-
1a expression is required but not sufficient for increased
expression of CD26.
The growth of tumors is known to be associated with
hypoxia and low extracellular pH in the tumor microen-
vironment [29]. In our experimental system, low extracel-
lular pH had no effect on CD26 protein expression,
regardless of the extent of cell confluence. On the other
hand, we found that depletion of serum factors was asso-
ciated with a robust upregulation of CD26. Furthermore,
the effect of serum depletion on CD26 protein expression
was reversible, as was also the case with c-Myc and HIF-
1a expression. All three proteins returned to basal level
of expression in 24 hours following culturing in regular
10% FBS medium. These results hence suggest that there
is a serum factor(s)-dependent regulatory mechanism for
CD26 protein expression, which affects cells maintained
without serum at sub-confluence. Since the half life of
CD26 protein in cells at post-confluence is reported to
be much longer than 48 hours as assayed by [
35S]-
methionine label pulse-chase experiments [9], our results
suggest the existence of an unidentified serum factor-
dependent degradative mechanism in the regulation of
CD26 protein expression. These data indicate that a
post-confluent state can be mimicked by cells at sub-con-
fluence by depleting required serum factors. While we
did not detect differences in CD26 expression when cells
were incubated in serum-free conditions with low levels
of BSA (data not shown), it is still theoretically possible
that the presence of BSA in the culture media of cells
cultured in serum-free conditions can interfere with
CD26 metabolism and expression. We would also like to
note that our observations are restricted to the specific
cells and proteins evaluated in our experimental condi-
tions, and are not necessarily applicable to other cell
types or proteins. When cells are at post-confluence,
depletion of nutrients is likely to limit cell growth. In
addition, tight junctions between cells growing at post-
confluence may inhibit binding of serum factors to the
cell surface, leading to the upregulation of CD26. How-
ever, the potential contribution of factors secreted from
cells at post-confluence cannot be excluded. In fact,
others have reported increased HIF-1a expression when
sub-confluent breast carcinoma cells were incubated with
conditioned media from confluent cultures [12].
Our previous studies demonstrated the potential of tar-
geted therapy using anti-CD26 mAb treatment in several
tumor models, including renal clear cell carcinoma and
malignant mesothelioma [7,8]. In these cell lines, upregu-
lation of p27
Kip1 was observed following treatment with
anti-CD26 mAb. We observed that p27
Kip1 expression
was elevated in cells treated with anti-CD26 mAb com-
pared to isotype-matched control mAb when treatment
was done in serum-depleted culture conditions (data not
shown). However, this anti-CD26 mAb-mediated
enhancement in p27
Kip1 level was not observed if cells
were incubated in serum-containing media, indicating
that serum depletion can enhance the effect of anti-CD26
mAb treatment in cells normally expressing low CD26
level (presumably by upregulating target expression).
Future studies will examine in detail the mechanism
associated with CD26 enhancement mediated by serum-
depleted culture conditions. This knowledge, combined
with our present findings, may prove to have clinical sig-
nificance by expanding the potential usage of anti-CD26
mAb therapy in selected human cancers through
enhanced CD26 expression.
Conclusions
In summary, we demonstrate that CD26 expression is
regulated in a confluence-dependent manner, involving
potentially transcriptional and posttranslational mechan-
isms. For the confluence-dependent increase in CD26
expression, decreased expression of c-Myc and increased
expression of USF-1 and Cdx2 may contribute to the
upregulation of CD26 expression at the transcriptional
level. Meanwhile, factors associated with serum depletion
may also contribute to increased CD26 expression, with
one potential mechanism being at the posttranslational
level by regulating an unknown serum factor-dependent
CD26 protein degradation pathway. Importantly, our pre-
sent findings may result in the expansion of the use of
CD26-targeted therapy in the clinical setting for selected
tumors by regulating the expression of CD26 itself.
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